Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
NK-Cell Leukemia
Non Hodgkin Lymphoma (NHL)
Juvenile Myelomonocytic Leukemia (JMML)
Chronic Myeloid Leukemia (CML)

Interventions: Drug: Cyclophosphamide
Biological: Fludarabine
Drug: Thiotepa
Drug: Melphalan
Biological: G-csf
Drug: Mesna
Device: CliniMACS
Biological: ATG (rabbit)
Drug: Blinatumomab
Biological: TCRα/β+
Biological: CD19+
Biological: CD45RA-depleted DLI

First Posted Date: 2019-02-21

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 140

Registration Number: NCT03849651

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Phase 1

Recruiting

Conditions: Hematologic Diseases
Chronic Myelogenous Leukemia, Accelerated Phase
Myelodysplastic Syndromes
Mantle Cell Lymphoma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Graft Vs Host Disease
Acute Leukemia in Remission
Chronic Myelogenous Leukemia, Blastic Phase
Non Hodgkin Lymphoma

Interventions: Drug: Vorinostat
Procedure: Blood and Marrow Transplant (BMT)
Drug: Tacrolimus (or cyclosporine)
Drug: Methotrexate
Drug: Mycophenolate Mofetil (MMF)
Drug: Cyclophosphamide

First Posted Date: 2019-02-15

Last Posted Date: 2024-04-02

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 49

Registration Number: NCT03842696

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 3 locations

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cervical Cancer
Advanced Solid Tumors
EGFR Positive Solid Tumor
Hepatocellular Carcinoma
Renal Cell Carcinoma
NSCLC
Urothelial Carcinoma
Colorectal Cancer
Small Cell Lung Cancer
Melanoma

Interventions: Drug: FT500
Drug: Cyclophosphamide
Drug: Nivolumab
Drug: Pembrolizumab
Drug: Atezolizumab
Drug: Fludarabine
Drug: IL-2

First Posted Date: 2019-02-15

Last Posted Date: 2023-05-01

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 37

Registration Number: NCT03841110

Locations: 🇺🇸
Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma

Interventions: Drug: Rituximab
Drug: Etoposide
Drug: Vincristine
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Cisplatin
Drug: Cytarabine

First Posted Date: 2019-02-12

Last Posted Date: 2022-01-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 118

Registration Number: NCT03837873

Locations: 🇨🇳
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
the First Affiliated Hospital of Jilin University, Changchun, Jilin, China

and more 3 locations

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Phase 2

Active, not recruiting

Conditions: Hepatocellular Carcinoma
Bladder Cancer
Microsatellite Instability-High
Ovarian Cancer
Non-small Cell Lung Cancer

Interventions: Other: DPX-Survivac
Drug: Pembrolizumab
Drug: Cyclophosphamide

First Posted Date: 2019-02-11

Last Posted Date: 2022-03-31

Lead Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.)

Target Recruit Count: 184

Registration Number: NCT03836352

Locations: 🇺🇸
Boca Raton Regional Hospital, Lynn Cancer Institute, Boca Raton, Florida, United States
🇨🇦
William Osler Health System, Brampton, Ontario, Canada
🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada

and more 20 locations

Autologous Transplant To End NMO Spectrum Disorder

Phase 2

Withdrawn

Conditions: Neuromyelitis Optica
Devic's Disease
NMO Spectrum Disorder

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: G-CSF
Biological: IVIg
Biological: Autologous Stem Cells

First Posted Date: 2019-02-04

Last Posted Date: 2019-11-20

Lead Sponsor: Northwestern University

Registration Number: NCT03829566

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Fludarabine
Drug: Alemtuzumab
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Mesna
Radiation: Total Body Irradiation (8Gy)

First Posted Date: 2019-01-30

Last Posted Date: 2024-05-16

Lead Sponsor: University of Birmingham

Target Recruit Count: 242

Registration Number: NCT03821610

Locations: 🇬🇧
Cardiff and Vale University Health Board, Cardiff, United Kingdom
🇬🇧
The Clatterbridge Cancer Centre Nhs Foundation Trust, Liverpool, United Kingdom
🇬🇧
University Hospitals of Leicester Nhs Trust, Leicester, United Kingdom

and more 19 locations

An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Phase 4

Completed

Conditions: Advanced Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Bendamustine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone/Prednisolone/Methylprednisolone
Drug: Vincristine

First Posted Date: 2019-01-28

Last Posted Date: 2024-04-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 114

Registration Number: NCT03817853

Locations: 🇳🇱
Albert Schweitzer Ziekenhuis - loc Dordrecht, Dordrecht, Netherlands
🇧🇷
NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil
🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States

and more 30 locations